Eli Lilly (LLY) SEC filings

Eli Lilly's latest annual report is a Form 10-K filed on February 12, 2026 for the period ended December 31, 2025. Its latest quarterly report, a Form 10-Q, was filed on October 29, 2026. Its latest current report, a Form 8-K, was filed on October 29, 2026 (2.02 Results of Operations and Financial Condition).

Key facts

Latest annual report
10-K, Feb 12, 2026
Latest quarterly report
10-Q, Oct 29, 2026
Latest 8-K
8-K, Oct 29, 2026
Filings, last 12 months
171
Insider forms, last 12 months
121Forms 3, 4 and 5
13D and 13G, last 12 months
11
SEC central index key
0000059478

Filings as listed by SEC EDGAR at (re-read at most hourly). Source: SEC EDGAR filings for CIK 0000059478. Every form links to its document on sec.gov. Older filings are in EDGAR's archive; the tables here cover its recent list (at least the last year).

Annual and quarterly reports

Eli Lilly: annual and quarterly reports filed with the SEC
FormFiledPeriod endedDocument
10-QQuarterly report
10-QQuarterly report
10-QQuarterly report
10-KAnnual report
10-QQuarterly report
10-QQuarterly report
10-QQuarterly report
10-KAnnual report
10-QQuarterly report
10-QQuarterly report
10-QQuarterly report
10-KAnnual report
10-QQuarterly report
10-QQuarterly report
10-QQuarterly report
10-KAnnual report

The latest 16 of 20 in EDGAR's recent list. Amended reports are marked. The period is the fiscal year or quarter the report covers.

Current reports (8-K)

Eli Lilly: current reports on Form 8-K and the items each reports
FormFiledEvent dateWhat it reports
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K8.01 Other Events9.01 Financial Statements and Exhibits
8-K5.07 Submission of Matters to a Vote of Security Holders
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K5.02 Departure or Election of Directors or Officers; Officer Compensation
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K8.01 Other Events9.01 Financial Statements and Exhibits
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K5.07 Submission of Matters to a Vote of Security Holders
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K8.01 Other Events9.01 Financial Statements and Exhibits
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K5.02 Departure or Election of Directors or Officers; Officer Compensation9.01 Financial Statements and Exhibits
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K5.02 Departure or Election of Directors or Officers; Officer Compensation9.01 Financial Statements and Exhibits
8-K5.02 Departure or Election of Directors or Officers; Officer Compensation9.01 Financial Statements and Exhibits
8-K8.01 Other Events9.01 Financial Statements and Exhibits

The latest 20 of 43 in EDGAR's recent list. Item names are the SEC's own, from Form 8-K (a few long ones shortened). The event date is the date of the earliest event reported.

Insider forms (3, 4 and 5)

Eli Lilly: insider forms 3, 4 and 5 filed per month over the last twelve months
MonthForms filed
Nov 20269
Oct 20266
Sep 20268
Aug 20268
Jul 20265
Jun 20265
May 20265
Apr 20264
Mar 20264
Feb 202632
Jan 20268
Dec 20259
Eli Lilly: the latest insider forms
FormFiledTransaction date
4
4
4
4
4
4
4
4
4
3
4
4
4
4
3
4
4
4
4
4

The latest 20 of 712 in EDGAR's recent list. Each form is filed by the insider about their own holding; the trade details are inside the form on sec.gov. Counts include amendments. The current month is counted to date.

Ownership reports (Schedules 13D and 13G)

Eli Lilly: Schedule 13D and 13G beneficial ownership reports
FormFiledEvent date
Schedule 13G (amended)—
Schedule 13D—
Schedule 13D—
Schedule 13G (amended)—
Schedule 13G—
Schedule 13G (amended)—
Schedule 13G—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13D—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—

The latest 20 of 43 in EDGAR's recent list. Filed by the holder, not the company. EDGAR's list names the form and date; who filed it is in the document.

Proxy statements

Eli Lilly: proxy statements and proxy materials
FormFiledMeeting or periodDocument
DEFA14A—
DEF 14ADefinitive proxy statement
PRE 14APreliminary proxy statement
DEFA14A—
DEF 14ADefinitive proxy statement
PRE 14APreliminary proxy statement
DEFA14A—
DEF 14ADefinitive proxy statement
PRE 14APreliminary proxy statement
DEFA14A—
DEF 14A—Definitive proxy statement
PRE 14A—Preliminary proxy statement
DEFA14A—
DEF 14ADefinitive proxy statement
PRE 14APreliminary proxy statement

Everything else (169 filings: registrations, prospectuses, Rule 144 notices, correspondence and more)
Eli Lilly: other SEC filings
FormFiledPeriodDocument
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
11-K
144—Notice of proposed sale
25-NSE—
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
SD—Specialized disclosure report
424B2—Prospectus
FWP—
144—Notice of proposed sale
424B2—Prospectus
PX14A6G—
DFAN14A—
144—Notice of proposed sale
SC TO-T (amended)—
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
SC TO-T—
144—Notice of proposed sale
144—Notice of proposed sale
SC TO-C—
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
424B2—Prospectus
FWP—
424B2—Prospectus
144—Notice of proposed sale
SC TO-T (amended)—
SC TO-T (amended)—
SC TO-T (amended)—
SC TO-T—
11-K
SC TO-C—
25-NSE—
144—Notice of proposed sale
SD—Specialized disclosure report
PX14A6G—
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
S-3ASR—Short-form registration statement
144—Notice of proposed sale
424B2—Prospectus
FWP—
144—Notice of proposed sale

The latest 60 of 169 in EDGAR's recent list.

What the forms are

Form 3 — Initial statement of beneficial ownership
An insider's first statement of holdings in the company's equity securities. Insiders are officers, directors and holders of more than 10 percent of a class of its registered equity securities.
Form 4 — Statement of changes in beneficial ownership
An insider's transactions in the company's equity securities, disclosed within two business days of the transaction.
Form 5 — Annual statement of beneficial ownership
An insider's annual statement of holdings in the company's equity securities.
Form 144 — Notice of proposed sale
In the SEC's Forms Index: notice of proposed sale of securities pursuant to Rule 144.
Form 10-K — Annual report
Audited annual financial statements, a discussion of material risk factors, and management's discussion and analysis of the results for the prior fiscal year.
Form 10-Q — Quarterly report
Unaudited quarterly financial statements, updates on material risks, and management's discussion and analysis of the results for the prior fiscal quarter.
Form 8-K — Current report
Discloses material events or information the company chooses or is required to make public before its next scheduled quarterly or annual report. Each report lists the items it covers.
Schedule 13D — Schedule 13D beneficial ownership report
Filed when a party acquires more than five percent of a class of the company's registered voting securities; also used to disclose later changes to the holding.
Schedule 13G — Schedule 13G beneficial ownership report
Filed when a party acquires more than five percent of a class of the company's registered voting securities as a passive investment.
Form DEF 14A — Definitive proxy statement
The final proxy statement sent to shareholders for a shareholder meeting: the matters to be voted on, and typically executive and board compensation and who owns more than five percent.
Form PRE 14A — Preliminary proxy statement
A preliminary proxy statement subject to review by the SEC staff.
Form S-3 — Short-form registration statement
An abbreviated registration statement available to certain already-reporting companies to register the offer and sale of securities to the public.
Form 424B — Prospectus
A document disclosing information about the company and an offering; it typically makes up a large part of the registration statement.
Form SD — Specialized disclosure report
In the SEC's Forms Index: Specialized Disclosure Report.

From the SEC's own descriptions: SEC, Using EDGAR to Research Investments; SEC, Forms Index; SEC, Form 8-K and its items (PDF).

Questions and answers

Where is Eli Lilly's latest annual report (10-K)?

Eli Lilly filed its latest Form 10-K with the SEC on February 12, 2026 for the period ended December 31, 2025. The table of annual and quarterly reports on this page links to the document on sec.gov.

When did Eli Lilly file its latest 10-Q?

On October 29, 2026 for the period ended September 30, 2026. A Form 10-Q holds unaudited quarterly financial statements and management's discussion of the quarter.

What has Eli Lilly reported on Form 8-K recently?

Its latest 8-K was filed on October 29, 2026 (2.02 Results of Operations and Financial Condition). In the last twelve months the items it reported most often were: 2.02 Results of Operations and Financial Condition (4 reports); 5.02 Departure or Election of Directors or Officers; Officer Compensation (1 report); 5.07 Submission of Matters to a Vote of Security Holders (1 report). An 8-K discloses material events before the next quarterly or annual report.

How many insider filings (Forms 3, 4 and 5) were there for LLY in the last year?

121 insider forms in the twelve months to November 17, 2026, the latest a Form 4 filed on November 10, 2026. Officers, directors and holders of more than 10 percent of a class of the company's registered equity securities must disclose their holdings and transactions; a Form 4 is due within two business days of a trade.

Has anyone reported owning more than 5% of Eli Lilly?

EDGAR lists 11 Schedule 13D or 13G filings about Eli Lilly in the last twelve months, the latest on October 19, 2026. These are filed by a party that acquires more than five percent of a class of the company's voting securities; 13G is for passive investors.

Cite this page

Funkfolio, “Eli Lilly (LLY) SEC filings: latest 10-K, 10-Q and 8-K”, data as of 17 November 2026. https://funkfolio.com/stock/LLY/filings

Underlying data: SEC EDGAR submissions (data.sec.gov).